Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 35 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 681

Topic: Biology, Genetics & Bone Healing

Regarding the highly organized ultrastructure of normal human articular cartilage, which zone is uniquely characterized by possessing the highest concentration of water, the lowest concentration of proteoglycans, and collagen fibrils that are oriented tightly parallel to the joint surface?

. Superficial (tangential) zone
. Transitional (middle) zone
. Deep (radial) zone
. Calcified cartilage zone
. Tidemark

Correct Answer & Explanation

. Superficial (tangential) zone

Explanation

Articular cartilage is divided into functionally distinct zones. The superficial (tangential) zone provides a gliding surface and resists shear forces. It has the highest water content (up to 80%), the lowest proteoglycan content, and densely packed collagen type II fibrils aligned parallel to the articular surface. Conversely, the deep (radial) zone has the highest proteoglycan content, the lowest water content, and collagen fibrils aligned perpendicular to the surface to resist compressive loads.

Question 682

Topic: Biology, Genetics & Bone Healing

Romosozumab is an anabolic agent used in the treatment of severe osteoporosis. It exerts its effect by binding to and inhibiting sclerostin. At a cellular level, what is the direct consequence of sclerostin inhibition in bone tissue?

. Activation of the RANKL pathway
. Stimulation of osteoclast apoptosis
. Facilitation of Wnt binding to LRP5/6 receptors
. Inhibition of Cathepsin K secretion
. Downregulation of Runx2 expression

Correct Answer & Explanation

. Facilitation of Wnt binding to LRP5/6 receptors

Explanation

Sclerostin, secreted by osteocytes, is a negative regulator of bone formation. It functions by binding to LRP5/6 receptors on osteoblasts, thereby antagonizing the canonical Wnt/beta-catenin signaling pathway. Romosozumab binds to sclerostin, preventing it from binding LRP5/6, which allows Wnt signaling to proceed uninhibited, leading to increased osteoblast differentiation and bone formation.

Question 683

Topic: Biology, Genetics & Bone Healing

A 32-year-old female undergoes intralesional curettage and cementation for a giant cell tumor (GCT) of the distal radius. Two years later, she presents with local recurrence. The multidisciplinary tumor board recommends a trial of Denosumab. By what mechanism does this drug target the tumor?

. Directly inducing apoptosis in the neoplastic giant cells
. Inhibiting vascular endothelial growth factor (VEGF) to reduce tumor angiogenesis
. Binding to RANKL to prevent osteoclast-mediated bone destruction
. Acting as an antagonist at the estrogen receptor
. Blocking the mammalian target of rapamycin (mTOR) pathway

Correct Answer & Explanation

. Binding to RANKL to prevent osteoclast-mediated bone destruction

Explanation

Denosumab is a fully human monoclonal antibody that targets Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). In GCT of bone, the neoplastic mononuclear stromal cells secrete high levels of RANKL, which recruits and activates the reactive multinucleated giant cells (osteoclast-like cells). Denosumab binds RANKL, inhibiting this activation, which reduces bone resorption and often induces intralesional ossification.

Question 684

Topic: Biology, Genetics & Bone Healing

A 35-year-old female presents with a lytic lesion in the distal femur. Biopsy confirms Giant Cell Tumor (GCT) of bone.

Due to the proximity to the joint and tumor size, the multidisciplinary tumor board recommends neoadjuvant treatment with denosumab prior to curettage. What is the specific molecular mechanism of action of denosumab in treating GCT?

. Direct induction of apoptosis in the neoplastic mononuclear cells
. Inhibition of vascular endothelial growth factor (VEGF) to reduce tumor angiogenesis
. Binding to RANK Ligand (RANKL), preventing activation of the RANK receptor on osteoclast-like giant cells
. Irreversible binding to hydroxyapatite crystals, inhibiting osteoclastic acid secretion
. Stimulation of osteoprotegerin (OPG) synthesis by osteoblasts

Correct Answer & Explanation

. Binding to RANK Ligand (RANKL), preventing activation of the RANK receptor on osteoclast-like giant cells

Explanation

Giant Cell Tumor of bone consists of neoplastic mononuclear cells that express high levels of RANK Ligand (RANKL), which recruits and activates reactive multi-nucleated osteoclast-like giant cells that cause the extensive bone destruction. Denosumab is a fully human monoclonal antibody that binds directly to RANKL. By neutralizing RANKL, denosumab prevents the interaction with the RANK receptor on the surface of osteoclast precursors and giant cells, thereby profoundly inhibiting osteolysis and allowing the tumor bed to ossify.

Question 685

Topic: Biology, Genetics & Bone Healing



A 28-year-old female presents with progressive knee pain. Radiographs show an eccentric, purely lytic lesion in the distal femoral epiphysis extending to the subchondral bone without a sclerotic rim. Biopsy reveals multinucleated giant cells in a background of mononuclear stromal cells. Which systemic therapy specifically targets the primary pathophysiology of this lesion?

. Denosumab
. Imatinib
. Doxorubicin
. Methotrexate
. Zoledronic acid

Correct Answer & Explanation

. Denosumab

Explanation

Giant Cell Tumor of Bone (GCTB) is characterized by neoplastic mononuclear stromal cells that express RANKL, which recruits and activates the reactive multinucleated osteoclast-like giant cells causing osteolysis. Denosumab is a monoclonal antibody against RANKL and is highly effective in the treatment of advanced, recurrent, or unresectable GCTB.

Question 686

Topic: Biology, Genetics & Bone Healing

Bone Morphogenetic Protein 2 (BMP-2) signals primarily through which intracellular cascade to stimulate osteoblastic differentiation and endochondral ossification?

. Wnt/beta-catenin pathway
. Smad 1/5/8 pathway
. JAK/STAT pathway
. Notch/Hes1 pathway
. MAP kinase pathway

Correct Answer & Explanation

. Smad 1/5/8 pathway

Explanation

BMPs bind to serine/threonine kinase receptors on the cell membrane, leading to the phosphorylation of receptor-regulated Smads (specifically Smad 1, 5, and 8). These phosphorylated Smads form a complex with Smad 4 (co-Smad) and translocate to the nucleus, where they regulate the transcription of osteogenic genes such as Runx2.

Question 687

Topic: Biology, Genetics & Bone Healing

A spiral fracture of the tibial shaft is treated with a reamed intramedullary nail, creating an environment of relative stability. During the reparative phase of secondary fracture healing, which of the following anatomic structures is the primary source of the cells that form the massive initial soft callus?

. Endosteum
. Periosteum
. Bone marrow cavity
. Circulating systemic mesenchymal stem cells
. Haversian canals

Correct Answer & Explanation

. Periosteum

Explanation

Secondary bone healing occurs in environments with relative stability (e.g., IM nailing, casting, bridge plating) and is characterized by callus formation. The primary source of cells for the initial bridging soft callus is the periosteum, specifically its inner cambium layer, which is highly cellular and rich in osteoprogenitor cells that rapidly proliferate and differentiate into chondrocytes and osteoblasts.

Question 688

Topic: Biology, Genetics & Bone Healing
A 62-year-old female presents with a pathologic subtrochanteric femur fracture. Her laboratory workup reveals hypercalcemia, anemia, and an elevated total serum protein. Serum protein electrophoresis demonstrates a monoclonal spike. Which of the following best describes the underlying pathophysiology responsible for the lytic bone lesions in this condition?
. Direct mechanical bone resorption by proliferating malignant plasma cells
. Secretion of RANKL and MIP-1alpha by tumor cells stimulating profound osteoclast activity
. Systemic secretion of parathyroid hormone-related peptide (PTHrP) from the primary tumor mass
. Decreased osteoblast function secondary to toxic accumulation of systemic bisphosphonates
. Tumor cell production of high levels of matrix metalloproteinases leading to primary cartilage and matrix destruction

Correct Answer & Explanation

. Secretion of RANKL and MIP-1alpha by tumor cells stimulating profound osteoclast activity

Explanation

Multiple myeloma, a malignancy of plasma cells, causes characteristic osteolytic bone lesions through an uncoupling of bone remodeling. Myeloma cells upregulate osteoclastogenesis by secreting factors such as Macrophage Inflammatory Protein-1 alpha (MIP-1α) and Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). Concurrently, they inhibit osteoblast activity (via factors like DKK1 and sclerostin). PTHrP is classically associated with solid metastatic tumors (e.g., breast, lung), not myeloma.

Question 689

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with persistent knee pain. Imaging reveals an eccentric, lytic epiphyseal lesion extending to the subchondral bone, characteristic of a giant cell tumor of bone.

She is prescribed denosumab prior to surgical intervention. What is the precise mechanism of action of this medication?

. Inhibits osteoclast ruffled border proton pumps
. Binds to RANK ligand (RANKL) preventing its interaction with the RANK receptor
. Binds to the RANK receptor preventing osteoclast differentiation
. Induces direct apoptosis of neoplastic osteoblasts
. Neutralizes parathyroid hormone-related peptide (PTHrP)

Correct Answer & Explanation

. Binds to RANK ligand (RANKL) preventing its interaction with the RANK receptor

Explanation

Denosumab is a human monoclonal antibody that binds specifically to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), a protein essential for the formation, function, and survival of osteoclasts. By neutralizing RANKL, denosumab prevents it from binding to the RANK receptor on osteoclast precursors, dramatically decreasing osteoclast-mediated bone destruction, which is the primary pathology in Giant Cell Tumor of Bone.

Question 690

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) play a crucial role in clinical osteoinduction by promoting the differentiation of mesenchymal stem cells into osteoblasts.

Which intracellular signaling pathway is primarily activated immediately following BMP receptor binding?

. Wnt/beta-catenin pathway
. JAK/STAT pathway
. Smad 1/5/8 pathway
. MAPK/ERK pathway
. Notch signaling pathway

Correct Answer & Explanation

. Smad 1/5/8 pathway

Explanation

BMPs are members of the TGF-beta superfamily. When a BMP binds to its specific transmembrane serine/threonine kinase receptor, it triggers the phosphorylation of receptor-regulated Smads (R-Smads), specifically Smad 1, 5, and 8. These phosphorylated Smads form a complex with Smad 4 (Co-Smad) and translocate to the nucleus to induce transcription of osteogenic genes like Runx2.

Question 691

Topic: Biology, Genetics & Bone Healing

During secondary fracture healing in the setting of relative stability, the fracture callus progresses through an endochondral ossification pathway. Which of the following transcription factors is fundamentally essential for the differentiation of mesenchymal stem cells into chondrocytes to form the initial soft callus?

. Runx2
. Sox9
. Osterix (Sp7)
. NFATc1
. Beta-catenin

Correct Answer & Explanation

. Sox9

Explanation

Secondary fracture healing relies heavily on endochondral ossification, beginning with a cartilaginous soft callus. Sox9 is the master transcription factor required for chondrocyte differentiation. Runx2 and Osterix are key transcription factors for osteoblast differentiation (membranous ossification and hard callus formation). NFATc1 is critical for osteoclastogenesis. Beta-catenin is a key component of the Wnt signaling pathway, which promotes osteoblastogenesis while actually suppressing chondrogenesis.

Question 692

Topic: Biology, Genetics & Bone Healing

A 35-year-old female is diagnosed with a locally aggressive giant cell tumor of the distal radius. Preoperative administration of Denosumab is planned to facilitate downstaging and joint-salvage surgery. What is the exact mechanism of action of Denosumab in this context?

. Monoclonal antibody that binds directly to the RANK receptor on the surface of osteoclasts
. Monoclonal antibody that binds to RANK Ligand (RANKL) preventing its interaction with RANK
. Small molecule inhibitor of the tyrosine kinase VEGF receptor preventing angiogenesis
. Bisphosphonate that induces osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase
. Selective estrogen receptor modulator (SERM) that enhances systemic osteoprotegerin (OPG) production

Correct Answer & Explanation

. Monoclonal antibody that binds to RANK Ligand (RANKL) preventing its interaction with RANK

Explanation

Denosumab is a fully human monoclonal antibody that specifically binds to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). By binding to RANKL, it prevents it from interacting with the RANK receptor on the surface of osteoclasts and osteoclast precursors. In Giant Cell Tumor of bone, the neoplastic mononuclear stromal cells express high levels of RANKL, which aggressively recruits and activates the reactive multinucleated giant cells (osteoclasts) that cause bone destruction.

Question 693

Topic: Biology, Genetics & Bone Healing



A 32-year-old female presents with progressive knee pain. Imaging reveals an eccentric, lytic, epiphyseal lesion in the proximal tibia extending to the subchondral bone without a sclerotic margin. Biopsy confirms multinucleated giant cells intermixed with mononuclear stromal cells. If targeted medical therapy is initiated prior to surgical curettage, what is the primary mechanism of action of the preferred agent?

. Inhibition of the tyrosine kinase domain of VEGFR
. Monoclonal antibody binding to RANK ligand (RANKL)
. Inhibition of the mammalian target of rapamycin (mTOR)
. Binding to the intracellular domain of the HER2 receptor
. Direct alkylation of DNA causing cross-linking

Correct Answer & Explanation

. Monoclonal antibody binding to RANK ligand (RANKL)

Explanation

The clinical and radiographic presentation is classic for a Giant Cell Tumor (GCT) of bone. Denosumab is a monoclonal antibody frequently used as neoadjuvant or primary medical therapy for aggressive or unresectable GCTs. It binds specifically to RANKL, preventing it from interacting with RANK receptors on osteoclast precursors and the giant cells themselves, thereby profoundly inhibiting osteoclastogenesis and tumor-associated bone destruction.

Question 694

Topic: Biology, Genetics & Bone Healing

A surgeon utilizes a non-vascularized cancellous autograft to augment fixation of a tibial nonunion. Which of the following best describes the primary biological process by which this specific graft incorporates into the host bone?

. Osteoinduction driven exclusively by exogenous bone morphogenetic proteins
. Endochondral ossification mediated by hypertrophic chondrocytes
. Creeping substitution where host osteoclasts resorb graft trabeculae while osteoblasts lay down new woven bone
. Intramembranous ossification originating entirely from the overlying muscle fascia
. Angiogenesis followed by the direct metabolic revival of all donor graft osteocytes

Correct Answer & Explanation

. Creeping substitution where host osteoclasts resorb graft trabeculae while osteoblasts lay down new woven bone

Explanation

Cancellous autografts incorporate primarily via a process called 'creeping substitution.' The graft acts as an osteoconductive scaffold. Over time, host-derived osteoclasts slowly resorb the dead graft trabeculae, while host-derived osteoblasts follow closely behind to deposit new woven (and eventually lamellar) bone onto the scaffold.

Question 695

Topic: Biology, Genetics & Bone Healing

Which of the following biomechanical conditions is required for primary (strain-free) bone healing to occur?

. Absolute stability and compression
. Relative stability with callus formation
. Intramedullary fixation with a gap
. External fixation with dynamization
. Cast immobilization

Correct Answer & Explanation

. Absolute stability and compression

Explanation

Primary bone healing (intramembranous ossification via cutting cones without callus formation) requires absolute stability (rigid fixation) and direct interfragmentary compression with no motion at the fracture site.

Question 696

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with knee pain. Radiographs reveal an eccentric, lytic lesion in the distal femoral epiphysis extending to the subchondral bone. Biopsy confirms a giant cell tumor. She is treated with denosumab preoperatively. What is the mechanism of action of denosumab?

. Inhibition of VEGF
. Monoclonal antibody against RANKL
. Direct cytotoxicity to osteoclasts
. Antagonist of the PTH receptor
. Inhibition of sclerostin

Correct Answer & Explanation

. Monoclonal antibody against RANKL

Explanation

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANK Ligand (RANKL). This prevents RANKL from activating RANK on the surface of osteoclasts and their precursors, thereby decreasing bone resorption and causing sclerosis in giant cell tumors.

Question 697

Topic: Biology, Genetics & Bone Healing

Following rigid internal fixation of a diaphyseal fracture with absolute stability, primary bone healing occurs without callus formation. This process is mediated primarily by:

. Endochondral ossification
. Intramembranous ossification
. Cutting cones crossing the fracture gap
. Fibrocartilage template conversion
. Chondrocyte hypertrophy

Correct Answer & Explanation

. Cutting cones crossing the fracture gap

Explanation

Absolute stability (e.g., compression plating) eliminates micro-motion at the fracture site, leading to primary bone healing. This occurs via direct Haversian remodeling where osteoclasts create "cutting cones" that cross the fracture site, followed by osteoblasts laying down new osteons, without a cartilaginous intermediate or visible callus.

Question 698

Topic: Biology, Genetics & Bone Healing

Fracture healing can occur via endochondral or intramembranous ossification. Intramembranous ossification occurs without a cartilaginous intermediate and is primarily seen in flat bones and during rigid plate fixation (primary bone healing). Which of the following transcription factors is the critical master regulator that directs multipotent mesenchymal stem cells down the osteoblastic lineage during intramembranous bone formation?

. SOX9
. MyoD
. RUNX2 (Cbfa1)
. PPAR-gamma
. HIF-1 alpha

Correct Answer & Explanation

. RUNX2 (Cbfa1)

Explanation

RUNX2 (also known as Cbfa1) is the master transcription factor required for osteoblast differentiation and is absolutely essential for both intramembranous and endochondral bone formation. Mice lacking RUNX2 are devoid of osteoblasts and completely lack bone. SOX9 is the master regulator for chondrocyte differentiation. PPAR-gamma regulates adipocyte differentiation. MyoD regulates myoblast differentiation.

Question 699

Topic: Biology, Genetics & Bone Healing

A 65-year-old female with known multiple myeloma presents with escalating back pain. Radiographs reveal diffuse osteopenia and multiple 'punched-out' lytic lesions in her vertebral bodies. The profound osteolysis seen in multiple myeloma is primarily driven by an imbalance in bone remodeling. Which of the following factors is directly secreted by myeloma cells to upregulate osteoclast activity via the RANK/RANKL pathway?

. Osteoprotegerin (OPG)
. Transforming growth factor-beta (TGF-beta)
. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)
. Bone morphogenetic protein-2 (BMP-2)
. Parathyroid hormone (PTH)

Correct Answer & Explanation

. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)

Explanation

Multiple myeloma bone lesions are characterized by uncoupled bone remodeling: increased osteoclast activity and markedly decreased osteoblast activity. Myeloma cells directly secrete several osteoclast activating factors, prominently Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha) and RANK Ligand (RANKL). They also suppress osteoblastogenesis via Dickkopf-1 (DKK-1) and sclerostin. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL and inhibits osteoclast activity; its levels are typically decreased in myeloma.

Question 700

Topic: Biology, Genetics & Bone Healing

Wnt/beta-catenin pathway activation in mesenchymal stem cells directly promotes differentiation into which of the following cell lineages?

. Chondrocytes
. Osteoblasts
. Osteoclasts
. Adipocytes
. Fibroblasts

Correct Answer & Explanation

. Osteoblasts

Explanation

Activation of the Wnt/beta-catenin signaling pathway in multipotent mesenchymal stem cells strongly directs them toward the osteoblastic lineage while simultaneously inhibiting chondrogenic and adipogenic differentiation. Beta-catenin translocates to the nucleus and interacts with TCF/LEF transcription factors to upregulate genes such as Runx2.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page